Testosterone Symptoms Supplement Injection
Testosterone Symptoms Supplement Injection


Is there a place for testosterone replacement?

Home
What's New - Blog
Abortion
Amenorrhoea - Absent Periods
Birth Control
Bladder Symptoms
Cancer in Women
Diet / Weight Loss
Dysmenorrhoea
Ectopic Pregnancy
Endometriosis
Female Sexual Problems
Fibroids
HRT Risks & Benefits
Hysterectomy
Infections
Infertility
Medication - Drugs
Menopause
Menorrhagia Heavy Periods
Miscarriage
Painful Sex - Dyspareunia
Pap Smear Test
PCOS
Pelvic Pain
PMS- Premenstrual Syndrome
Pregnancy & Childbirth
Vaginal Discharge
Vaginal Prolapse
Viagra, Libido and Sex Drive.
The Author
Consultations
Contact Us


Obstet Gynecol. 2005 May;105(5 Pt 1):944-52

Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial.

Buster JE,Kingsberg SA,Aguirre O,Brown C,Breaux JG,Buch A,Rodenberg CA,Wekselman K,Casson P.

Baylor College of Medicine, Houston, Texas, USA. jbuster@bcm. Tmc.edu

Objectives:

To assess the efficacy and safety of a 300 mug/d testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women on concomitant estrogen therapy.

Methods:

Five hundred thirty-three women with hypoactive sexual desire disorder who had undergone previous hysterectomy and bilateral oophorectomy were enrolled in a 24-week, multicenter, double-blind, placebo-controlled trial. Patients were randomly assigned to receive placebo or the testosterone patch twice weekly. The primary efficacy endpoint was change from baseline at week 24 in the Frequency of total satisfying sexual activity, measured by the Sexual Activity Log. Secondary measures included sexual desire using the Profile of Female Sexual Function and personal distress as measured by the Personal Distress Scale. Hormone levels, adverse events, and clinical laboratory measures were reviewed.

Results:

Total satisfying sexual activity significantly improved in the testosterone patch group compared with placebo after 24 weeks (mean change from baseline, 1.56 compared with 0.73 episodes per 4 weeks, P = .001). Treatment with the testosterone patch also significantly improved sexual desire (mean change, 10.57 compared with 4.29, P< .001) and decreased personal distress (P = .009). Serum free, total, and bioavailable testosterone concentrations increased from baseline. Overall, adverse events were similar in both groups (P > .05). The incidence of androgenic adverse events was higher in the testosterone group; most androgenic adverse events were mild.

Conclusion:

In surgically menopausal women with hypoactive sexual desire disorder, a 300 mug/d testosterone patch significantly increased satisfying sexual activity and sexual desire, while decreasing personal distress, and was well tolerated through up to 24 weeks of use.


Back Home Up Next

Please click on the required question.

Do you have an unanswered women's health question?

Please let us have your general question on our NEW FORUM / MESSAGE BOARDS facility and we will try to answer it for you. I am sure that you will appreciate that we cannot offer advice on the management of an individual's specific problem.


Thank you for your visiting us at 2WomensHealth.com.

This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London.

I do hope that you find the answers to your questions in the patient information and medical advice provided. If you still have unanswered questions, please consider entering them into one of our forums and I will try to assist you.

DISCLAIMER

The aim of this web site is to provide a general guide and it is not intended as a substitute for a consultation with an appropriate specialist in respect of individual care and treatment.

Testosterone Symptoms Supplement Injection